

Global Recombinant Insulin Glargine Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

<https://marketpublishers.com/r/GC316F0880C6EN.html>

Date: November 2025

Pages: 109

Price: US\$ 3,480.00 (Single User License)

ID: GC316F0880C6EN

Abstracts

According to our (Global Info Research) latest study, the global Recombinant Insulin Glargine market size was valued at US\$ 8359 million in 2024 and is forecast to a readjusted size of USD 7139 million by 2031 with a CAGR of -2.3% during review period.

In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.

Recombinant Insulin Glargine is a long-acting, human insulin analog produced using recombinant DNA technology. It is designed to provide a steady, peakless release of insulin over 24 hours to help control blood glucose levels in patients with diabetes mellitus. By modifying the insulin molecule's amino acid sequence, insulin glargine forms microprecipitates in subcutaneous tissue, allowing for slow and consistent absorption.

This report is a detailed and comprehensive analysis for global Recombinant Insulin Glargine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Recombinant Insulin Glargine market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2020-2031

Global Recombinant Insulin Glargine market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2020-2031

Global Recombinant Insulin Glargine market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2020-2031

Global Recombinant Insulin Glargine market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Recombinant Insulin Glargine

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Recombinant Insulin Glargine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Eli Lilly & Co, Biocon Biologics, Gan & Lee, Tonghua Dongbao, Biocare, United Laboratories, KALBE PHARMA, Swixx Biopharma, INFION PHARMA, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Recombinant Insulin Glargine market is split by Type and by Application. For the period

2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Vial

Prefilled

Market segment by Application

Type 1 Diabetes

Type 2 Diabetes

Major players covered

Sanofi

Eli Lilly & Co

Biocon Biologics

Gan & Lee

Tonghua Dongbao

Biocare

United Laboratories

KALBE PHARMA

Swixx Biopharma

INFION PHARMA

Viartis

Wockhardt

Lupin Laboratories

Cipla

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Recombinant Insulin Glargine product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Recombinant Insulin Glargine, with price, sales quantity, revenue, and global market share of Recombinant Insulin Glargine from 2020 to 2025.

Chapter 3, the Recombinant Insulin Glargine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Recombinant Insulin Glargine breakdown data are shown at the regional

level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025. and Recombinant Insulin Glargine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Recombinant Insulin Glargine.

Chapter 14 and 15, to describe Recombinant Insulin Glargine sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Market Analysis by Type

1.3.1 Overview: Global Recombinant Insulin Glargine Consumption Value by Type: 2020 Versus 2024 Versus 2031

1.3.2 Vial

1.3.3 Prefilled

1.4 Market Analysis by Application

1.4.1 Overview: Global Recombinant Insulin Glargine Consumption Value by Application: 2020 Versus 2024 Versus 2031

1.4.2 Type 1 Diabetes

1.4.3 Type 2 Diabetes

1.5 Global Recombinant Insulin Glargine Market Size & Forecast

1.5.1 Global Recombinant Insulin Glargine Consumption Value (2020 & 2024 & 2031)

1.5.2 Global Recombinant Insulin Glargine Sales Quantity (2020-2031)

1.5.3 Global Recombinant Insulin Glargine Average Price (2020-2031)

2 MANUFACTURERS PROFILES

2.1 Sanofi

2.1.1 Sanofi Details

2.1.2 Sanofi Major Business

2.1.3 Sanofi Recombinant Insulin Glargine Product and Services

2.1.4 Sanofi Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)

2.1.5 Sanofi Recent Developments/Updates

2.2 Eli Lilly & Co

2.2.1 Eli Lilly & Co Details

2.2.2 Eli Lilly & Co Major Business

2.2.3 Eli Lilly & Co Recombinant Insulin Glargine Product and Services

2.2.4 Eli Lilly & Co Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)

2.2.5 Eli Lilly & Co Recent Developments/Updates

2.3 Biocon Biologics

2.3.1 Biocon Biologics Details

- 2.3.2 Biocon Biologics Major Business
- 2.3.3 Biocon Biologics Recombinant Insulin Glargine Product and Services
- 2.3.4 Biocon Biologics Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.3.5 Biocon Biologics Recent Developments/Updates
- 2.4 Gan & Lee
 - 2.4.1 Gan & Lee Details
 - 2.4.2 Gan & Lee Major Business
 - 2.4.3 Gan & Lee Recombinant Insulin Glargine Product and Services
 - 2.4.4 Gan & Lee Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.4.5 Gan & Lee Recent Developments/Updates
- 2.5 Tonghua Dongbao
 - 2.5.1 Tonghua Dongbao Details
 - 2.5.2 Tonghua Dongbao Major Business
 - 2.5.3 Tonghua Dongbao Recombinant Insulin Glargine Product and Services
 - 2.5.4 Tonghua Dongbao Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.5.5 Tonghua Dongbao Recent Developments/Updates
- 2.6 Biocare
 - 2.6.1 Biocare Details
 - 2.6.2 Biocare Major Business
 - 2.6.3 Biocare Recombinant Insulin Glargine Product and Services
 - 2.6.4 Biocare Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.6.5 Biocare Recent Developments/Updates
- 2.7 United Laboratories
 - 2.7.1 United Laboratories Details
 - 2.7.2 United Laboratories Major Business
 - 2.7.3 United Laboratories Recombinant Insulin Glargine Product and Services
 - 2.7.4 United Laboratories Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.7.5 United Laboratories Recent Developments/Updates
- 2.8 KALBE PHARMA
 - 2.8.1 KALBE PHARMA Details
 - 2.8.2 KALBE PHARMA Major Business
 - 2.8.3 KALBE PHARMA Recombinant Insulin Glargine Product and Services
 - 2.8.4 KALBE PHARMA Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)

- 2.8.5 KALBE PHARMA Recent Developments/Updates
- 2.9 Swixx Biopharma
 - 2.9.1 Swixx Biopharma Details
 - 2.9.2 Swixx Biopharma Major Business
 - 2.9.3 Swixx Biopharma Recombinant Insulin Glargine Product and Services
 - 2.9.4 Swixx Biopharma Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.9.5 Swixx Biopharma Recent Developments/Updates
- 2.10 INFION PHARMA
 - 2.10.1 INFION PHARMA Details
 - 2.10.2 INFION PHARMA Major Business
 - 2.10.3 INFION PHARMA Recombinant Insulin Glargine Product and Services
 - 2.10.4 INFION PHARMA Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.10.5 INFION PHARMA Recent Developments/Updates
- 2.11 Viatris
 - 2.11.1 Viatris Details
 - 2.11.2 Viatris Major Business
 - 2.11.3 Viatris Recombinant Insulin Glargine Product and Services
 - 2.11.4 Viatris Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.11.5 Viatris Recent Developments/Updates
- 2.12 Wockhardt
 - 2.12.1 Wockhardt Details
 - 2.12.2 Wockhardt Major Business
 - 2.12.3 Wockhardt Recombinant Insulin Glargine Product and Services
 - 2.12.4 Wockhardt Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.12.5 Wockhardt Recent Developments/Updates
- 2.13 Lupin Laboratories
 - 2.13.1 Lupin Laboratories Details
 - 2.13.2 Lupin Laboratories Major Business
 - 2.13.3 Lupin Laboratories Recombinant Insulin Glargine Product and Services
 - 2.13.4 Lupin Laboratories Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
 - 2.13.5 Lupin Laboratories Recent Developments/Updates
- 2.14 Cipla
 - 2.14.1 Cipla Details
 - 2.14.2 Cipla Major Business

- 2.14.3 Cipla Recombinant Insulin Glargine Product and Services
- 2.14.4 Cipla Recombinant Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.14.5 Cipla Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: RECOMBINANT INSULIN GLARGINE BY MANUFACTURER

- 3.1 Global Recombinant Insulin Glargine Sales Quantity by Manufacturer (2020-2025)
- 3.2 Global Recombinant Insulin Glargine Revenue by Manufacturer (2020-2025)
- 3.3 Global Recombinant Insulin Glargine Average Price by Manufacturer (2020-2025)
- 3.4 Market Share Analysis (2024)
 - 3.4.1 Producer Shipments of Recombinant Insulin Glargine by Manufacturer Revenue (\$MM) and Market Share (%): 2024
 - 3.4.2 Top 3 Recombinant Insulin Glargine Manufacturer Market Share in 2024
 - 3.4.3 Top 6 Recombinant Insulin Glargine Manufacturer Market Share in 2024
- 3.5 Recombinant Insulin Glargine Market: Overall Company Footprint Analysis
 - 3.5.1 Recombinant Insulin Glargine Market: Region Footprint
 - 3.5.2 Recombinant Insulin Glargine Market: Company Product Type Footprint
 - 3.5.3 Recombinant Insulin Glargine Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

- 4.1 Global Recombinant Insulin Glargine Market Size by Region
 - 4.1.1 Global Recombinant Insulin Glargine Sales Quantity by Region (2020-2031)
 - 4.1.2 Global Recombinant Insulin Glargine Consumption Value by Region (2020-2031)
 - 4.1.3 Global Recombinant Insulin Glargine Average Price by Region (2020-2031)
- 4.2 North America Recombinant Insulin Glargine Consumption Value (2020-2031)
- 4.3 Europe Recombinant Insulin Glargine Consumption Value (2020-2031)
- 4.4 Asia-Pacific Recombinant Insulin Glargine Consumption Value (2020-2031)
- 4.5 South America Recombinant Insulin Glargine Consumption Value (2020-2031)
- 4.6 Middle East & Africa Recombinant Insulin Glargine Consumption Value (2020-2031)

5 MARKET SEGMENT BY TYPE

- 5.1 Global Recombinant Insulin Glargine Sales Quantity by Type (2020-2031)
- 5.2 Global Recombinant Insulin Glargine Consumption Value by Type (2020-2031)

5.3 Global Recombinant Insulin Glargine Average Price by Type (2020-2031)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Recombinant Insulin Glargine Sales Quantity by Application (2020-2031)

6.2 Global Recombinant Insulin Glargine Consumption Value by Application (2020-2031)

6.3 Global Recombinant Insulin Glargine Average Price by Application (2020-2031)

7 NORTH AMERICA

7.1 North America Recombinant Insulin Glargine Sales Quantity by Type (2020-2031)

7.2 North America Recombinant Insulin Glargine Sales Quantity by Application (2020-2031)

7.3 North America Recombinant Insulin Glargine Market Size by Country

7.3.1 North America Recombinant Insulin Glargine Sales Quantity by Country (2020-2031)

7.3.2 North America Recombinant Insulin Glargine Consumption Value by Country (2020-2031)

7.3.3 United States Market Size and Forecast (2020-2031)

7.3.4 Canada Market Size and Forecast (2020-2031)

7.3.5 Mexico Market Size and Forecast (2020-2031)

8 EUROPE

8.1 Europe Recombinant Insulin Glargine Sales Quantity by Type (2020-2031)

8.2 Europe Recombinant Insulin Glargine Sales Quantity by Application (2020-2031)

8.3 Europe Recombinant Insulin Glargine Market Size by Country

8.3.1 Europe Recombinant Insulin Glargine Sales Quantity by Country (2020-2031)

8.3.2 Europe Recombinant Insulin Glargine Consumption Value by Country (2020-2031)

8.3.3 Germany Market Size and Forecast (2020-2031)

8.3.4 France Market Size and Forecast (2020-2031)

8.3.5 United Kingdom Market Size and Forecast (2020-2031)

8.3.6 Russia Market Size and Forecast (2020-2031)

8.3.7 Italy Market Size and Forecast (2020-2031)

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Recombinant Insulin Glargine Sales Quantity by Type (2020-2031)
- 9.2 Asia-Pacific Recombinant Insulin Glargine Sales Quantity by Application (2020-2031)
- 9.3 Asia-Pacific Recombinant Insulin Glargine Market Size by Region
 - 9.3.1 Asia-Pacific Recombinant Insulin Glargine Sales Quantity by Region (2020-2031)
 - 9.3.2 Asia-Pacific Recombinant Insulin Glargine Consumption Value by Region (2020-2031)
 - 9.3.3 China Market Size and Forecast (2020-2031)
 - 9.3.4 Japan Market Size and Forecast (2020-2031)
 - 9.3.5 South Korea Market Size and Forecast (2020-2031)
 - 9.3.6 India Market Size and Forecast (2020-2031)
 - 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
 - 9.3.8 Australia Market Size and Forecast (2020-2031)

10 SOUTH AMERICA

- 10.1 South America Recombinant Insulin Glargine Sales Quantity by Type (2020-2031)
- 10.2 South America Recombinant Insulin Glargine Sales Quantity by Application (2020-2031)
- 10.3 South America Recombinant Insulin Glargine Market Size by Country
 - 10.3.1 South America Recombinant Insulin Glargine Sales Quantity by Country (2020-2031)
 - 10.3.2 South America Recombinant Insulin Glargine Consumption Value by Country (2020-2031)
 - 10.3.3 Brazil Market Size and Forecast (2020-2031)
 - 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 MIDDLE EAST & AFRICA

- 11.1 Middle East & Africa Recombinant Insulin Glargine Sales Quantity by Type (2020-2031)
- 11.2 Middle East & Africa Recombinant Insulin Glargine Sales Quantity by Application (2020-2031)
- 11.3 Middle East & Africa Recombinant Insulin Glargine Market Size by Country
 - 11.3.1 Middle East & Africa Recombinant Insulin Glargine Sales Quantity by Country (2020-2031)
 - 11.3.2 Middle East & Africa Recombinant Insulin Glargine Consumption Value by Country (2020-2031)
 - 11.3.3 Turkey Market Size and Forecast (2020-2031)

- 11.3.4 Egypt Market Size and Forecast (2020-2031)
- 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
- 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 MARKET DYNAMICS

- 12.1 Recombinant Insulin Glargine Market Drivers
- 12.2 Recombinant Insulin Glargine Market Restraints
- 12.3 Recombinant Insulin Glargine Trends Analysis
- 12.4 Porters Five Forces Analysis
 - 12.4.1 Threat of New Entrants
 - 12.4.2 Bargaining Power of Suppliers
 - 12.4.3 Bargaining Power of Buyers
 - 12.4.4 Threat of Substitutes
 - 12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

- 13.1 Raw Material of Recombinant Insulin Glargine and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Recombinant Insulin Glargine
- 13.3 Recombinant Insulin Glargine Production Process
- 13.4 Industry Value Chain Analysis

14 SHIPMENTS BY DISTRIBUTION CHANNEL

- 14.1 Sales Channel
 - 14.1.1 Direct to End-User
 - 14.1.2 Distributors
- 14.2 Recombinant Insulin Glargine Typical Distributors
- 14.3 Recombinant Insulin Glargine Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

- 16.1 Methodology
- 16.2 Research Process and Data Source
- 16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Recombinant Insulin Glargine Consumption Value by Type, (USD Million), 2020 & 2024 & 2031

Table 2. Global Recombinant Insulin Glargine Consumption Value by Application, (USD Million), 2020 & 2024 & 2031

Table 3. Sanofi Basic Information, Manufacturing Base and Competitors

Table 4. Sanofi Major Business

Table 5. Sanofi Recombinant Insulin Glargine Product and Services

Table 6. Sanofi Recombinant Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 7. Sanofi Recent Developments/Updates

Table 8. Eli Lilly & Co Basic Information, Manufacturing Base and Competitors

Table 9. Eli Lilly & Co Major Business

Table 10. Eli Lilly & Co Recombinant Insulin Glargine Product and Services

Table 11. Eli Lilly & Co Recombinant Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 12. Eli Lilly & Co Recent Developments/Updates

Table 13. Biocon Biologics Basic Information, Manufacturing Base and Competitors

Table 14. Biocon Biologics Major Business

Table 15. Biocon Biologics Recombinant Insulin Glargine Product and Services

Table 16. Biocon Biologics Recombinant Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 17. Biocon Biologics Recent Developments/Updates

Table 18. Gan & Lee Basic Information, Manufacturing Base and Competitors

Table 19. Gan & Lee Major Business

Table 20. Gan & Lee Recombinant Insulin Glargine Product and Services

Table 21. Gan & Lee Recombinant Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 22. Gan & Lee Recent Developments/Updates

Table 23. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors

Table 24. Tonghua Dongbao Major Business

Table 25. Tonghua Dongbao Recombinant Insulin Glargine Product and Services

Table 26. Tonghua Dongbao Recombinant Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 27. Tonghua Dongbao Recent Developments/Updates

Table 28. Biocare Basic Information, Manufacturing Base and Competitors

Table 29. Biocare Major Business

Table 30. Biocare Recombinant Insulin Glargine Product and Services

Table 31. Biocare Recombinant Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 32. Biocare Recent Developments/Updates

Table 33. United Laboratories Basic Information, Manufacturing Base and Competitors

Table 34. United Laboratories Major Business

Table 35. United Laboratories Recombinant Insulin Glargine Product and Services

Table 36. United Laboratories Recombinant Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 37. United Laboratories Recent Developments/Updates

Table 38. KALBE PHARMA Basic Information, Manufacturing Base and Competitors

Table 39. KALBE PHARMA Major Business

Table 40. KALBE PHARMA Recombinant Insulin Glargine Product and Services

Table 41. KALBE PHARMA Recombinant Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 42. KALBE PHARMA Recent Developments/Updates

Table 43. Swixx Biopharma Basic Information, Manufacturing Base and Competitors

Table 44. Swixx Biopharma Major Business

Table 45. Swixx Biopharma Recombinant Insulin Glargine Product and Services

Table 46. Swixx Biopharma Recombinant Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 47. Swixx Biopharma Recent Developments/Updates

Table 48. INFION PHARMA Basic Information, Manufacturing Base and Competitors

Table 49. INFION PHARMA Major Business

Table 50. INFION PHARMA Recombinant Insulin Glargine Product and Services

Table 51. INFION PHARMA Recombinant Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 52. INFION PHARMA Recent Developments/Updates

Table 53. Viartis Basic Information, Manufacturing Base and Competitors

Table 54. Viartis Major Business

Table 55. Viartis Recombinant Insulin Glargine Product and Services

Table 56. Viartis Recombinant Insulin Glargine Sales Quantity (K Units), Average Price

(US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 57. Viartis Recent Developments/Updates

Table 58. Wockhardt Basic Information, Manufacturing Base and Competitors

Table 59. Wockhardt Major Business

Table 60. Wockhardt Recombinant Insulin Glargine Product and Services

Table 61. Wockhardt Recombinant Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 62. Wockhardt Recent Developments/Updates

Table 63. Lupin Laboratories Basic Information, Manufacturing Base and Competitors

Table 64. Lupin Laboratories Major Business

Table 65. Lupin Laboratories Recombinant Insulin Glargine Product and Services

Table 66. Lupin Laboratories Recombinant Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 67. Lupin Laboratories Recent Developments/Updates

Table 68. Cipla Basic Information, Manufacturing Base and Competitors

Table 69. Cipla Major Business

Table 70. Cipla Recombinant Insulin Glargine Product and Services

Table 71. Cipla Recombinant Insulin Glargine Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 72. Cipla Recent Developments/Updates

Table 73. Global Recombinant Insulin Glargine Sales Quantity by Manufacturer (2020-2025) & (K Units)

Table 74. Global Recombinant Insulin Glargine Revenue by Manufacturer (2020-2025) & (USD Million)

Table 75. Global Recombinant Insulin Glargine Average Price by Manufacturer (2020-2025) & (US\$/Unit)

Table 76. Market Position of Manufacturers in Recombinant Insulin Glargine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024

Table 77. Head Office and Recombinant Insulin Glargine Production Site of Key Manufacturer

Table 78. Recombinant Insulin Glargine Market: Company Product Type Footprint

Table 79. Recombinant Insulin Glargine Market: Company Product Application Footprint

Table 80. Recombinant Insulin Glargine New Market Entrants and Barriers to Market Entry

Table 81. Recombinant Insulin Glargine Mergers, Acquisition, Agreements, and Collaborations

Table 82. Global Recombinant Insulin Glargine Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR

Table 83. Global Recombinant Insulin Glargine Sales Quantity by Region (2020-2025) & (K Units)

Table 84. Global Recombinant Insulin Glargine Sales Quantity by Region (2026-2031) & (K Units)

Table 85. Global Recombinant Insulin Glargine Consumption Value by Region (2020-2025) & (USD Million)

Table 86. Global Recombinant Insulin Glargine Consumption Value by Region (2026-2031) & (USD Million)

Table 87. Global Recombinant Insulin Glargine Average Price by Region (2020-2025) & (US\$/Unit)

Table 88. Global Recombinant Insulin Glargine Average Price by Region (2026-2031) & (US\$/Unit)

Table 89. Global Recombinant Insulin Glargine Sales Quantity by Type (2020-2025) & (K Units)

Table 90. Global Recombinant Insulin Glargine Sales Quantity by Type (2026-2031) & (K Units)

Table 91. Global Recombinant Insulin Glargine Consumption Value by Type (2020-2025) & (USD Million)

Table 92. Global Recombinant Insulin Glargine Consumption Value by Type (2026-2031) & (USD Million)

Table 93. Global Recombinant Insulin Glargine Average Price by Type (2020-2025) & (US\$/Unit)

Table 94. Global Recombinant Insulin Glargine Average Price by Type (2026-2031) & (US\$/Unit)

Table 95. Global Recombinant Insulin Glargine Sales Quantity by Application (2020-2025) & (K Units)

Table 96. Global Recombinant Insulin Glargine Sales Quantity by Application (2026-2031) & (K Units)

Table 97. Global Recombinant Insulin Glargine Consumption Value by Application (2020-2025) & (USD Million)

Table 98. Global Recombinant Insulin Glargine Consumption Value by Application (2026-2031) & (USD Million)

Table 99. Global Recombinant Insulin Glargine Average Price by Application (2020-2025) & (US\$/Unit)

Table 100. Global Recombinant Insulin Glargine Average Price by Application (2026-2031) & (US\$/Unit)

Table 101. North America Recombinant Insulin Glargine Sales Quantity by Type (2020-2025) & (K Units)

Table 102. North America Recombinant Insulin Glargine Sales Quantity by Type

(2026-2031) & (K Units)

Table 103. North America Recombinant Insulin Glargine Sales Quantity by Application (2020-2025) & (K Units)

Table 104. North America Recombinant Insulin Glargine Sales Quantity by Application (2026-2031) & (K Units)

Table 105. North America Recombinant Insulin Glargine Sales Quantity by Country (2020-2025) & (K Units)

Table 106. North America Recombinant Insulin Glargine Sales Quantity by Country (2026-2031) & (K Units)

Table 107. North America Recombinant Insulin Glargine Consumption Value by Country (2020-2025) & (USD Million)

Table 108. North America Recombinant Insulin Glargine Consumption Value by Country (2026-2031) & (USD Million)

Table 109. Europe Recombinant Insulin Glargine Sales Quantity by Type (2020-2025) & (K Units)

Table 110. Europe Recombinant Insulin Glargine Sales Quantity by Type (2026-2031) & (K Units)

Table 111. Europe Recombinant Insulin Glargine Sales Quantity by Application (2020-2025) & (K Units)

Table 112. Europe Recombinant Insulin Glargine Sales Quantity by Application (2026-2031) & (K Units)

Table 113. Europe Recombinant Insulin Glargine Sales Quantity by Country (2020-2025) & (K Units)

Table 114. Europe Recombinant Insulin Glargine Sales Quantity by Country (2026-2031) & (K Units)

Table 115. Europe Recombinant Insulin Glargine Consumption Value by Country (2020-2025) & (USD Million)

Table 116. Europe Recombinant Insulin Glargine Consumption Value by Country (2026-2031) & (USD Million)

Table 117. Asia-Pacific Recombinant Insulin Glargine Sales Quantity by Type (2020-2025) & (K Units)

Table 118. Asia-Pacific Recombinant Insulin Glargine Sales Quantity by Type (2026-2031) & (K Units)

Table 119. Asia-Pacific Recombinant Insulin Glargine Sales Quantity by Application (2020-2025) & (K Units)

Table 120. Asia-Pacific Recombinant Insulin Glargine Sales Quantity by Application (2026-2031) & (K Units)

Table 121. Asia-Pacific Recombinant Insulin Glargine Sales Quantity by Region (2020-2025) & (K Units)

Table 122. Asia-Pacific Recombinant Insulin Glargine Sales Quantity by Region (2026-2031) & (K Units)

Table 123. Asia-Pacific Recombinant Insulin Glargine Consumption Value by Region (2020-2025) & (USD Million)

Table 124. Asia-Pacific Recombinant Insulin Glargine Consumption Value by Region (2026-2031) & (USD Million)

Table 125. South America Recombinant Insulin Glargine Sales Quantity by Type (2020-2025) & (K Units)

Table 126. South America Recombinant Insulin Glargine Sales Quantity by Type (2026-2031) & (K Units)

Table 127. South America Recombinant Insulin Glargine Sales Quantity by Application (2020-2025) & (K Units)

Table 128. South America Recombinant Insulin Glargine Sales Quantity by Application (2026-2031) & (K Units)

Table 129. South America Recombinant Insulin Glargine Sales Quantity by Country (2020-2025) & (K Units)

Table 130. South America Recombinant Insulin Glargine Sales Quantity by Country (2026-2031) & (K Units)

Table 131. South America Recombinant Insulin Glargine Consumption Value by Country (2020-2025) & (USD Million)

Table 132. South America Recombinant Insulin Glargine Consumption Value by Country (2026-2031) & (USD Million)

Table 133. Middle East & Africa Recombinant Insulin Glargine Sales Quantity by Type (2020-2025) & (K Units)

Table 134. Middle East & Africa Recombinant Insulin Glargine Sales Quantity by Type (2026-2031) & (K Units)

Table 135. Middle East & Africa Recombinant Insulin Glargine Sales Quantity by Application (2020-2025) & (K Units)

Table 136. Middle East & Africa Recombinant Insulin Glargine Sales Quantity by Application (2026-2031) & (K Units)

Table 137. Middle East & Africa Recombinant Insulin Glargine Sales Quantity by Country (2020-2025) & (K Units)

Table 138. Middle East & Africa Recombinant Insulin Glargine Sales Quantity by Country (2026-2031) & (K Units)

Table 139. Middle East & Africa Recombinant Insulin Glargine Consumption Value by Country (2020-2025) & (USD Million)

Table 140. Middle East & Africa Recombinant Insulin Glargine Consumption Value by Country (2026-2031) & (USD Million)

Table 141. Recombinant Insulin Glargine Raw Material

Table 142. Key Manufacturers of Recombinant Insulin Glargine Raw Materials

Table 143. Recombinant Insulin Glargine Typical Distributors

Table 144. Recombinant Insulin Glargine Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Recombinant Insulin Glargine Picture

Figure 2. Global Recombinant Insulin Glargine Revenue by Type, (USD Million), 2020 & 2024 & 2031

Figure 3. Global Recombinant Insulin Glargine Revenue Market Share by Type in 2024

Figure 4. Vial Examples

Figure 5. Prefilled Examples

Figure 6. Global Recombinant Insulin Glargine Consumption Value by Application, (USD Million), 2020 & 2024 & 2031

Figure 7. Global Recombinant Insulin Glargine Revenue Market Share by Application in 2024

Figure 8. Type 1 Diabetes Examples

Figure 9. Type 2 Diabetes Examples

Figure 10. Global Recombinant Insulin Glargine Consumption Value, (USD Million): 2020 & 2024 & 2031

Figure 11. Global Recombinant Insulin Glargine Consumption Value and Forecast (2020-2031) & (USD Million)

Figure 12. Global Recombinant Insulin Glargine Sales Quantity (2020-2031) & (K Units)

Figure 13. Global Recombinant Insulin Glargine Price (2020-2031) & (US\$/Unit)

Figure 14. Global Recombinant Insulin Glargine Sales Quantity Market Share by Manufacturer in 2024

Figure 15. Global Recombinant Insulin Glargine Revenue Market Share by Manufacturer in 2024

Figure 16. Producer Shipments of Recombinant Insulin Glargine by Manufacturer Sales (\$MM) and Market Share (%): 2024

Figure 17. Top 3 Recombinant Insulin Glargine Manufacturer (Revenue) Market Share in 2024

Figure 18. Top 6 Recombinant Insulin Glargine Manufacturer (Revenue) Market Share in 2024

Figure 19. Global Recombinant Insulin Glargine Sales Quantity Market Share by Region (2020-2031)

Figure 20. Global Recombinant Insulin Glargine Consumption Value Market Share by Region (2020-2031)

Figure 21. North America Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 22. Europe Recombinant Insulin Glargine Consumption Value (2020-2031) &

(USD Million)

Figure 23. Asia-Pacific Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 24. South America Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 25. Middle East & Africa Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 26. Global Recombinant Insulin Glargine Sales Quantity Market Share by Type (2020-2031)

Figure 27. Global Recombinant Insulin Glargine Consumption Value Market Share by Type (2020-2031)

Figure 28. Global Recombinant Insulin Glargine Average Price by Type (2020-2031) & (US\$/Unit)

Figure 29. Global Recombinant Insulin Glargine Sales Quantity Market Share by Application (2020-2031)

Figure 30. Global Recombinant Insulin Glargine Revenue Market Share by Application (2020-2031)

Figure 31. Global Recombinant Insulin Glargine Average Price by Application (2020-2031) & (US\$/Unit)

Figure 32. North America Recombinant Insulin Glargine Sales Quantity Market Share by Type (2020-2031)

Figure 33. North America Recombinant Insulin Glargine Sales Quantity Market Share by Application (2020-2031)

Figure 34. North America Recombinant Insulin Glargine Sales Quantity Market Share by Country (2020-2031)

Figure 35. North America Recombinant Insulin Glargine Consumption Value Market Share by Country (2020-2031)

Figure 36. United States Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 37. Canada Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 38. Mexico Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 39. Europe Recombinant Insulin Glargine Sales Quantity Market Share by Type (2020-2031)

Figure 40. Europe Recombinant Insulin Glargine Sales Quantity Market Share by Application (2020-2031)

Figure 41. Europe Recombinant Insulin Glargine Sales Quantity Market Share by Country (2020-2031)

Figure 42. Europe Recombinant Insulin Glargine Consumption Value Market Share by Country (2020-2031)

Figure 43. Germany Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 44. France Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 45. United Kingdom Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 46. Russia Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 47. Italy Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 48. Asia-Pacific Recombinant Insulin Glargine Sales Quantity Market Share by Type (2020-2031)

Figure 49. Asia-Pacific Recombinant Insulin Glargine Sales Quantity Market Share by Application (2020-2031)

Figure 50. Asia-Pacific Recombinant Insulin Glargine Sales Quantity Market Share by Region (2020-2031)

Figure 51. Asia-Pacific Recombinant Insulin Glargine Consumption Value Market Share by Region (2020-2031)

Figure 52. China Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 53. Japan Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 54. South Korea Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 55. India Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 56. Southeast Asia Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 57. Australia Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 58. South America Recombinant Insulin Glargine Sales Quantity Market Share by Type (2020-2031)

Figure 59. South America Recombinant Insulin Glargine Sales Quantity Market Share by Application (2020-2031)

Figure 60. South America Recombinant Insulin Glargine Sales Quantity Market Share by Country (2020-2031)

Figure 61. South America Recombinant Insulin Glargine Consumption Value Market

Share by Country (2020-2031)

Figure 62. Brazil Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 63. Argentina Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 64. Middle East & Africa Recombinant Insulin Glargine Sales Quantity Market Share by Type (2020-2031)

Figure 65. Middle East & Africa Recombinant Insulin Glargine Sales Quantity Market Share by Application (2020-2031)

Figure 66. Middle East & Africa Recombinant Insulin Glargine Sales Quantity Market Share by Country (2020-2031)

Figure 67. Middle East & Africa Recombinant Insulin Glargine Consumption Value Market Share by Country (2020-2031)

Figure 68. Turkey Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 69. Egypt Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 70. Saudi Arabia Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 71. South Africa Recombinant Insulin Glargine Consumption Value (2020-2031) & (USD Million)

Figure 72. Recombinant Insulin Glargine Market Drivers

Figure 73. Recombinant Insulin Glargine Market Restraints

Figure 74. Recombinant Insulin Glargine Market Trends

Figure 75. Porters Five Forces Analysis

Figure 76. Manufacturing Cost Structure Analysis of Recombinant Insulin Glargine in 2024

Figure 77. Manufacturing Process Analysis of Recombinant Insulin Glargine

Figure 78. Recombinant Insulin Glargine Industrial Chain

Figure 79. Sales Channel: Direct to End-User vs Distributors

Figure 80. Direct Channel Pros & Cons

Figure 81. Indirect Channel Pros & Cons

Figure 82. Methodology

Figure 83. Research Process and Data Source

I would like to order

Product name: Global Recombinant Insulin Glargine Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Product link: <https://marketpublishers.com/r/GC316F0880C6EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC316F0880C6EN.html>